Which testosterone preparation is most appropriate for subcutaneous injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Subcutaneous Testosterone: Optimal Formulation

Testosterone enanthate or cypionate are the best preparations for subcutaneous injection, started at 50-100 mg weekly, as these formulations achieve therapeutic testosterone levels equivalent to intramuscular administration with superior tolerability. 1

Recommended Formulations for SubQ Administration

  • Testosterone enanthate and testosterone cypionate are equally effective for subcutaneous injection, with both demonstrating dose-proportional pharmacokinetics and steady serum testosterone profiles when dosed weekly 1, 2

  • Testosterone undecanoate is NOT recommended for subcutaneous use as it must be administered as gluteal intramuscular injection only, despite one research study showing technical feasibility 1

Dosing Protocol for SubQ Testosterone

  • Start at 50-100 mg weekly via subcutaneous injection, which provides more stable testosterone levels compared to biweekly intramuscular dosing 1

  • Dose range of 50-150 mg weekly is effective across a wide BMI range (19.0 to 49.9 kg/m²), with median effective dose of 75-80 mg in clinical studies 1, 2

  • Target mid-normal testosterone levels of 450-600 ng/dL measured midway between injections at 2-3 months after initiation or dose adjustment 1

Clinical Advantages of SubQ Route

  • SubQ injection achieves therapeutic testosterone levels equivalent to IM administration with no significant difference in total testosterone exposure (mean AUC 1.7 vs 1.9 nmol·days/L/mg) 3

  • Superior tolerability compared to IM injection, with lower patient-reported scores for pre-injection anxiety, pain during injection, and post-injection pain 3

  • Easier self-administration using shorter needles (typically 27-gauge, five-eighths inch) compared to the 21-23 gauge, 1-1.5 inch needles required for IM gluteal or thigh injections 1, 4

  • 92.7% of patients achieve target testosterone levels (300-1,100 ng/dL) with dose-adjusted subcutaneous testosterone enanthate, with more than 95% reporting no injection-related pain 5

Injection Technique and Sites

  • Abdomen and thigh are appropriate subcutaneous injection sites for testosterone, though specific anatomical guidance is limited in current guidelines 1

  • Use smaller gauge needles (27-gauge, five-eighths inch) which are adequate for subcutaneous administration of testosterone in oil-based vehicles 4

  • Minor and transient local reactions occur in approximately 14% of patients (9 out of 63) but do not typically require discontinuation 2

Monitoring Requirements

  • Measure testosterone levels at 2-3 months after initiation or any dose change, checking midway between injections and targeting 450-600 ng/dL 1

  • Monitor hematocrit/hemoglobin at each visit, as injectable testosterone (including SubQ) carries risk of erythrocytosis, though weekly dosing reduces this risk compared to biweekly administration 1

  • Once stable levels achieved, monitor every 6-12 months including testosterone, hematocrit, PSA (if age-appropriate), and lipid profiles 1

Critical Safety Considerations

  • Weekly SubQ dosing produces more stable testosterone levels than biweekly IM dosing, which reduces adverse effects including erythrocytosis and potentially cardiovascular risk 1

  • Erythrocytosis occurs in 43.8% with IM injections versus 15.4% with transdermal preparations, though specific SubQ rates are not well-defined; weekly dosing mitigates peak supraphysiological levels 1

  • No clinically significant hepatotoxicity occurs with injectable testosterone enanthate or cypionate, as these formulations bypass first-pass hepatic metabolism and are not 17-α-alkylated 1

Common Pitfalls to Avoid

  • Do not use testosterone undecanoate subcutaneously in routine practice, as it is FDA-approved only for gluteal IM injection despite one research study showing technical feasibility 1, 6

  • Do not assume SubQ requires different total weekly doses than IM administration; the same 50-100 mg weekly starting dose applies to both routes 1, 2

  • Do not forget to prescribe appropriate supplies: 27-gauge needles for SubQ (not the 21-23 gauge, 1-1.5 inch needles used for IM), 1-3 mL syringes, alcohol prep pads, and sharps container 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.